The resulting ISR induction also makes B-cell leukemia 2 protein (BCL-2) inhibition therapy in AML more effective by decreasing the expression of a known resistance factor for BCL-2 inhibition, myeloid cell leukemia-1 (151). This evidence concerns the gene BCL2 and acute myeloid leukemia.